These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Subscribe To Our Newsletter & Stay Updated
